Recursion Pharmaceuticals-a Earnings

Recursion Pharmaceuticals-a’s revenue jumped 32.5% since last year same period to $19.1Mn in the Q2 2025. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated 29.56% jump in its revenue since last 3-months.

Recursion Pharmaceuticals-a’s net profit fell -76.23% since last year same period to $-171.9Mn in the Q2 2025. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated 15.11% jump in its net profits since last 3-months.

Recursion Pharmaceuticals-a’s net profit margin fell -33% since last year same period to -899.84% in the Q2 2025. On a quarterly growth basis, Recursion Pharmaceuticals-a has generated 34.47% jump in its net profit margins since last 3-months.

Recursion Pharmaceuticals-a’s earning per share (EPS) estimates for the current quarter stand at -0.34 - a 2.86% jump from last quarter’s estimates.

Recursion Pharmaceuticals-a’s earning per share (EPS) estimates for the current year stand at -0.34.

Recursion Pharmaceuticals-a’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Recursion Pharmaceuticals-a has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.